Search Results
Dr. Sramila Aithal Describes the HERceptin Adjuvant (HERA) Trial for HER2-Positive Breast Cancer
Dr. Sramila Aithal on the EMILIA Trial Studying T-DM1 in Metastatic Breast Cancer
Dr. Sanft on Treatment Options in HER2-Positive Breast Cancer
Dr. Yardley on the RESPECT Trial in HER2-Positive Breast Cancer
Neo-PATH: TAHP for patients with HER2-positive breast cancer
Extended adjuvant therapy for HER2-positive early breast cancer
Next wave of successful drug therapy strategies in HER2-positive breast cancer
Dr. Sramila Aithal on the AE37 Peptide Vaccine in Breast Cancer
The PERSEPHONE trial: 6 months and 12 months of trastuzumab in breast cancer
Dr. Sramila Aithal MD; Director Breast Cancer of Advanced Oncology; Shares Life's Journey & Devotion
Dr. Brian Leyland-Jones Reviews the Phase III HERA Trial
Assessing a Case of Early-Stage HER2+ Breast Cancer
